1-10 of 10
Jun Zhou
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade

Open Access
Xiaoyu Li, Jingjing Li, Yue Zheng, Sandra J. Lee, Jun Zhou, Anita Giobbie-Hurder, Lisa H. Butterfield, Glenn Dranoff, F. Stephen Hodi
Journal: Cancer Immunology Research
Cancer Immunol Res (2023) 11 (8): 1100–1113.
https://doi.org/10.1158/2326-6066.CIR-22-0702
Published: 03 August 2023
View articletitled, Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade
Open the PDF for Granulocyte–Macrophage Colony-Stimulating Factor Influence on Soluble and Membrane-Bound ICOS in Combination with Immune Checkpoint Blockade in another window
Includes: Supplementary data
Journal Articles

The Gut Microbiome Is Associated with Clinical Response to Anti–PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer

Available to Purchase
Zhi Peng, Siyuan Cheng, Yan Kou, Ziqi Wang, Rong Jin, Han Hu, Xiaotian Zhang, Ji-fang Gong, Jian Li, Ming Lu, Xicheng Wang, Jun Zhou, ZhiHao Lu, Quan Zhang, David T.W. Tzeng, Dongtao Bi, Yan Tan, Lin Shen
Journal: Cancer Immunology Research
Cancer Immunol Res (2020) 8 (10): 1251–1261.
https://doi.org/10.1158/2326-6066.CIR-19-1014
Published: 01 October 2020
View articletitled, The Gut Microbiome Is Associated with Clinical Response to Anti–PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer
Open the PDF for The Gut Microbiome Is Associated with Clinical Response to Anti–PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer in another window
Includes: Supplementary data
Journal Articles

Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade

Free
Jun Zhou, Kathleen M. Mahoney, Anita Giobbie-Hurder, Fengmin Zhao, Sandra Lee, Xiaoyun Liao, Scott Rodig, Jingjing Li, Xinqi Wu, Lisa H. Butterfield, Matthias Piesche, Michael P. Manos, Lauren M. Eastman, Glenn Dranoff, Gordon J. Freeman, F. Stephen Hodi
Journal: Cancer Immunology Research
Series: Author Choice
Cancer Immunol Res (2017) 5 (6): 480–492.
https://doi.org/10.1158/2326-6066.CIR-16-0329
Published: 01 June 2017
View articletitled, Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
Open the PDF for Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade in another window
Includes: Supplementary data
Journal Articles

Combined Anti-VEGF and Anti–CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes

Free
Xinqi Wu, Jingjing Li, Erin M. Connolly, Xiaoyun Liao, Jing Ouyang, Anita Giobbie-Hurder, Donald Lawrence, David McDermott, George Murphy, Jun Zhou, Matthias Piesche, Glenn Dranoff, Scott Rodig, Margaret Shipp, F. Stephen Hodi
Journal: Cancer Immunology Research
Cancer Immunol Res (2017) 5 (6): 446–454.
https://doi.org/10.1158/2326-6066.CIR-16-0385
Published: 01 June 2017
View articletitled, Combined Anti-VEGF and Anti–CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes
Open the PDF for Combined Anti-VEGF and Anti–CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes in another window
Includes: Supplementary data
Journal Articles

Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy

Free
Xinqi Wu, Anita Giobbie-Hurder, Xiaoyun Liao, Courtney Connelly, Erin M. Connolly, Jingjing Li, Michael P. Manos, Donald Lawrence, David McDermott, Mariano Severgnini, Jun Zhou, Evisa Gjini, Ana Lako, Mikel Lipschitz, Christine J. Pak, Sara Abdelrahman, Scott Rodig, F. Stephen Hodi
Journal: Cancer Immunology Research
Cancer Immunol Res (2017) 5 (1): 17–28.
https://doi.org/10.1158/2326-6066.CIR-16-0206
Published: 03 January 2017
View articletitled, Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy
Open the PDF for Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy in another window
Includes: Supplementary data
Journal Articles

VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma

Free
Xinqi Wu, Anita Giobbie-Hurder, Xiaoyun Liao, Donald Lawrence, David McDermott, Jun Zhou, Scott Rodig, F. Stephen Hodi
Journal: Cancer Immunology Research
Cancer Immunol Res (2016) 4 (10): 858–868.
https://doi.org/10.1158/2326-6066.CIR-16-0084
Published: 02 October 2016
View articletitled, VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma
Open the PDF for VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma in another window
Includes: Supplementary data
Journal Articles

Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model

Free
David A. Reardon, Prafulla C. Gokhale, Sarah R. Klein, Keith L. Ligon, Scott J. Rodig, Shakti H. Ramkissoon, Kristen L. Jones, Amy Saur Conway, Xiaoyun Liao, Jun Zhou, Patrick Y. Wen, Annick D. Van Den Abbeele, F. Stephen Hodi, Lei Qin, Nancy E. Kohl, Arlene H. Sharpe, Glenn Dranoff, Gordon J. Freeman
Journal: Cancer Immunology Research
Cancer Immunol Res (2016) 4 (2): 124–135.
https://doi.org/10.1158/2326-6066.CIR-15-0151
Published: 01 February 2016
View articletitled, Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model
Open the PDF for Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model in another window
Includes: Supplementary data
Journal Articles

Immunity to the Vacuolar ATPase Complex Accessory Unit ATP6S1 in Patients with Malignant Melanoma

Free
Jun Zhou, Meghna Gupta, Xinqi Wu, Charles Yoon, Anita Giobbie-Hurder, F. Stephen Hodi
Journal: Cancer Immunology Research
Cancer Immunol Res (2015) 3 (1): 59–67.
https://doi.org/10.1158/2326-6066.CIR-14-0184
Published: 06 January 2015
View articletitled, Immunity to the Vacuolar ATPase Complex Accessory Unit ATP6S1 in Patients with Malignant Melanoma
Open the PDF for Immunity to the Vacuolar ATPase Complex Accessory Unit ATP6S1 in Patients with Malignant Melanoma in another window
Includes: Supplementary data
Journal Articles

Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

Free
F. Stephen Hodi, Donald Lawrence, Cecilia Lezcano, Xinqi Wu, Jun Zhou, Tetsuro Sasada, Wanyong Zeng, Anita Giobbie-Hurder, Michael B. Atkins, Nageatte Ibrahim, Philip Friedlander, Keith T. Flaherty, George F. Murphy, Scott Rodig, Elsa F. Velazquez, Martin C. Mihm, Jr, Sara Russell, Pamela J. DiPiro, Jeffrey T. Yap, Nikhil Ramaiya, Annick D. Van den Abbeele, Maria Gargano, David McDermott
Journal: Cancer Immunology Research
Cancer Immunol Res (2014) 2 (7): 632–642.
https://doi.org/10.1158/2326-6066.CIR-14-0053
Published: 01 July 2014
View articletitled, Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
Open the PDF for Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma in another window
Includes: Supplementary data
Journal Articles

Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab

Free
Jianda Yuan, Jun Zhou, Zhiwan Dong, Sapna Tandon, Deborah Kuk, Katherine S. Panageas, Philip Wong, Xinqi Wu, Jarushka Naidoo, David B. Page, Jedd D. Wolchok, F. Stephen Hodi
Journal: Cancer Immunology Research
Cancer Immunol Res (2014) 2 (2): 127–132.
https://doi.org/10.1158/2326-6066.CIR-13-0163
Published: 03 February 2014
View articletitled, Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab
Open the PDF for Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab in another window